Literature DB >> 33994734

Neuropeptide Substance P Enhances Inflammation-Mediated Tumor Signaling Pathways and Migration and Proliferation of Head and Neck Cancers.

Sumeet Singh1, Subhashree Kumaravel1, Saurabh Dhole1, Sukanya Roy1, Vani Pavan1, Sanjukta Chakraborty1.   

Abstract

Head and neck cancers (HNC) are extremely aggressive, highly recurrent, and the sixth most common cancer worldwide. Neuropeptide substance P, along with its primary receptor, neurokinin-1 (NK-1R), is overexpressed in HNC and is a central player in inflammation and growth and metastasis of several cancers. However, the precise SP-mediated signaling that promotes HNC progression remains ill defined. Using a panel of HNC lines, in this study, we investigated the effects of SP on proliferation and migration of HNC. Tumor cells were also treated with SP and alterations in inflammatory cytokines and chemokines, and their cognate receptors were analyzed by real-time PCR. Furthermore, we investigated the role of SP in inducing epithelial-mesenchymal transition (EMT), and matrix metalloproteases that promote tumor invasion. Our results showed that SP significantly increased tumor cell proliferation and migration and induced the expression of several genes that promote tumor growth, invasion, and metastasis which was suppressed by a specific NK1R antagonist L-703606. SP also activated NFκB that was suppressed on inhibiting NK1R. Collectively, our data shows that SP-NK1R-mediated inflammatory signaling comprises an important signaling axis in promoting HNC and may prove to be effective clinical target against HNC cells that are resistant to traditional therapy. © Indian Association of Surgical Oncology 2020.

Entities:  

Keywords:  Cytokines; Head neck cancer; Inflammation; Neuropeptide; Tumor progression

Year:  2020        PMID: 33994734      PMCID: PMC8119571          DOI: 10.1007/s13193-020-01210-7

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  37 in total

1.  CXCL11-CXCR3 Axis Mediates Tumor Lymphatic Cross Talk and Inflammation-Induced Tumor, Promoting Pathways in Head and Neck Cancers.

Authors:  Subhashree Kumaravel; Sumeet Singh; Sukanya Roy; Lavanya Venkatasamy; Tori K White; Samiran Sinha; Shannon S Glaser; Stephen H Safe; Sanjukta Chakraborty
Journal:  Am J Pathol       Date:  2020-02-05       Impact factor: 4.307

2.  Interleukin 12 and antigen independently induce substance P receptor expression in T cells in murine schistosomiasis mansoni.

Authors:  A M Blum; A Metwali; C Crawford; J Li; K Qadir; D E Elliott; J V Weinstock
Journal:  FASEB J       Date:  2001-04       Impact factor: 5.191

3.  Hyperglycemia- and hyperinsulinemia-induced insulin resistance causes alterations in cellular bioenergetics and activation of inflammatory signaling in lymphatic muscle.

Authors:  Yang Lee; James D Fluckey; Sanjukta Chakraborty; Mariappan Muthuchamy
Journal:  FASEB J       Date:  2017-03-15       Impact factor: 5.191

4.  Survival After Distant Metastasis in Head and Neck Cancer.

Authors:  Susanne Wiegand; Annette Zimmermann; Thomas Wilhelm; Jochen A Werner
Journal:  Anticancer Res       Date:  2015-10       Impact factor: 2.480

Review 5.  The emerging role of substance P/neurokinin-1 receptor signaling pathways in growth and development of tumor cells.

Authors:  Hossein Javid; Fariba Mohammadi; Elnaz Zahiri; Seyed Isaac Hashemy
Journal:  J Physiol Biochem       Date:  2019-08-01       Impact factor: 4.158

6.  Substance P induces inflammatory responses involving NF-κB in genetically diabetic mice skin fibroblasts co-cultured with macrophages.

Authors:  Tao Ni; Yushu Liu; Yinbo Peng; Ming Li; Yong Fang; Min Yao
Journal:  Am J Transl Res       Date:  2016-05-15       Impact factor: 4.060

7.  Neurotransmitter substance P mediates pancreatic cancer perineural invasion via NK-1R in cancer cells.

Authors:  Xuqi Li; Guodong Ma; Qingyong Ma; Wei Li; Jiangbo Liu; Liang Han; Wanxing Duan; Qinhong Xu; Han Liu; Zheng Wang; Qing Sun; Fengfei Wang; Erxi Wu
Journal:  Mol Cancer Res       Date:  2013-01-23       Impact factor: 5.852

Review 8.  Involvement of substance P and the NK-1 receptor in cancer progression.

Authors:  Miguel Muñoz; Rafael Coveñas
Journal:  Peptides       Date:  2013-08-07       Impact factor: 3.750

9.  A role for the substance P/NK-1 receptor complex in cell proliferation in oral squamous cell carcinoma.

Authors:  Sylvie Brener; Miguel Angel González-Moles; Denise Tostes; Francisco Esteban; Jose Antonio Gil-Montoya; Isabel Ruiz-Avila; Manuel Bravo; Miguel Muñoz
Journal:  Anticancer Res       Date:  2009-06       Impact factor: 2.480

Review 10.  Neurokinin-1 Receptor Antagonists against Hepatoblastoma.

Authors:  Miguel Muñoz; Marisa Rosso; Rafael Coveñas
Journal:  Cancers (Basel)       Date:  2019-08-28       Impact factor: 6.639

View more
  4 in total

1.  Potential in vitro therapeutic effects of targeting SP/NK1R system in cervical cancer.

Authors:  Mahtab Mozafari; Safieh Ebrahimi; Reza Assaran Darban; Seyed Isaac Hashemy
Journal:  Mol Biol Rep       Date:  2021-11-12       Impact factor: 2.316

Review 2.  Substance P and Neurokinin 1 Receptor in Chronic Inflammation and Cancer of the Head and Neck: A Review of the Literature.

Authors:  Francisco Esteban; Pablo Ramos-García; Miguel Muñoz; Miguel Ángel González-Moles
Journal:  Int J Environ Res Public Health       Date:  2021-12-30       Impact factor: 3.390

3.  Tumor Lymphatic Interactions Induce CXCR2-CXCL5 Axis and Alter Cellular Metabolism and Lymphangiogenic Pathways to Promote Cholangiocarcinoma.

Authors:  Sukanya Roy; Subhashree Kumaravel; Priyanka Banerjee; Tori K White; April O'Brien; Catherine Seelig; Rahul Chauhan; Burcin Ekser; Kayla J Bayless; Gianfranco Alpini; Shannon S Glaser; Sanjukta Chakraborty
Journal:  Cells       Date:  2021-11-09       Impact factor: 7.666

4.  The Potential In Vitro Inhibitory Effects of Neurokinin-1 Receptor (NK-1R) Antagonist, Aprepitant, in Osteosarcoma Cell Migration and Metastasis.

Authors:  Mohammed Ali Alsaeed; Safieh Ebrahimi; Abbas Alalikhan; Seyedeh Fatemeh Hashemi; Seyed Isaac Hashemy
Journal:  Biomed Res Int       Date:  2022-09-20       Impact factor: 3.246

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.